Business
IceCure Medical Reports First Quarter 2023 Financial & Operational Results
Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational CoursesProSense was the
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational CoursesProSense was the only Cryoablation System Used in a First-of-its-Kind Cryotherapy Continuing Medical Education (CME) course at the American Society of Breast Surgeons (ASBrS) 2023 Annual Meeting Where a Plan was Presented for a Proposed ASBrS Cryoablation TrialRegulatory Approval Received in China for Commercial Use of Disposable CryoprobesIndependently Conducted Endometriosis Study Shows 92.8% Efficacy in Avoiding Secondary SurgeryConference Call to be Held Today at 10:00 am Eastern TimeCAESAREA, Israel, May 22, 2023 /PRNewswire/-- IceCure Medical Ltd. (the \"Company\" or \"IceCure\") (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2023 as well as operational and recent corporate developments.\n\"ProSense is gaining heightened interest among breast surgeons, breast radiologists, and interventional oncologists globally and particularly in the U.S. where we are focusing our commercialization and marketing efforts. We believe this momentum in the market is bolstered by a broader trend toward minimally invasive procedures,\" stated IceCure CEO Eyal Shamir.\n\"We continue to engage with the U.S. Food and Drug Administration (\"FDA\") following the October 2022 filing for marketing authorization for ProSense for early-stage low risk breast cancer in patients who are at high risk for surgery. These ongoing discussions are part of the regulatory submission process. Concurrently, we are highly encouraged by the American Society of Breast Surgeons' (\"ASBrS\") expressed plans for a cryoablation trial. We believe that such a planned trial could potentially establish a new minimally invasive standard for the treatment of low risk, early-stage breast cancer. We further believe it will support our commercialization plans, and raise awareness among ASBrS members, which include 3,000 of the most influential physicians in breast surgery.\n\"Globally, we continue to build momentum through regulatory submissions and approvals including in China where our IceSense3 system and cryoprobes are now...